Literature DB >> 21762293

HCV prevalence and co-infection with HIV among pregnant women in Saint Camille Medical Centre, Ouagadougou.

Moctar T A Zeba1, Simplice D Karou, Tani Sagna, Florencia Djigma, Cyrille Bisseye, Djeneba Ouermi, Virginio Pietra, Salvatore Pignatelli, Charlemagne Gnoula, Joseph D Sia, Remy Moret, Jean-Baptiste Nikiema, Jacques Simpore.   

Abstract

OBJECTIVE: To determine hepatitis C virus (HCV) prevalence and the rate of HCV/human immunodeficiency virus (HIV) co-infection in pregnant women attending Saint Camille medical centre (SCMC) in Ouagadougou.
METHODS: A total of 607 pregnant women, 16-45 years old, with <32 weeks amenorrhoea were screened for HCV and HIV using rapid tests. The majority of the women included in the study were previously known as HIV infected, as the centre is a reference centre for the programme of prevention against mother-to-child HIV transmission in the country. HCV RNA was extracted and quantified using the cDNA polymerase chain reaction with the nested primers at the 5' untranslated region. Transaminases were measured from plasma samples using spectrophotometric method.
RESULTS: Of women, 62.27% were infected with HIV. The prevalence of HCV was 2.14% in the screened pregnant women: 1.75% in HIV-negative women and 2.38% in HIV-positive ones. This prevalence is not significantly different between HIV-positive and HIV-negative pregnant women (P = 0.81). HCV RNA was found in all women with anti-HCV. A significant transaminase increase was noted in women infected with HCV (P = 0.01 and P < 0.01 for glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase, respectively). Risk factors significantly associated with HCV positivity in pregnant women included transfusion and genital excision. In addition, the infection was linked with the educational level of the women.
CONCLUSION: The issue of this study revealed that effort should be made to promote safe medical practices and fight against women genital excision that are found to be the main risk factors associated with the HCV infection.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21762293     DOI: 10.1111/j.1365-3156.2011.02845.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  6 in total

1.  Epidemiological profiles of human immunodeficiency virus and hepatitis C virus infections in Malian women: Risk factors and relevance of disparities.

Authors:  Nouhoum Bouare; Andre Gothot; Jean Delwaide; Sebastien Bontems; Dolores Vaira; Laurence Seidel; Paul Gerard; Christiane Gerard
Journal:  World J Hepatol       Date:  2013-04-27

2.  Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso.

Authors:  Moctar Tokèda Abdoul Zeba; Mahamoudou Sanou; Cyrille Bisseye; Alice Kiba; Bolni Marius Nagalo; Florencia Wendkuuni Djigma; Tegwindé Rebecca Compaoré; Yacouba Koumpingnin Nebié; Kisito Kienou; Tani Sagna; Virginio Pietra; Rémy Moret; Jacques Simporé
Journal:  Blood Transfus       Date:  2014-01       Impact factor: 3.443

3.  Prevalence and Risk Factors of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Pregnant Women Attending Antenatal Care at a Tertiary Hospital in Abuja, Nigeria.

Authors:  Chris Ovoroyeguono Agboghoroma; Binyerem Chigbonwu Ukaire
Journal:  Niger Med J       Date:  2020-10-13

4.  Development, coinfection, and the syndemics of pregnancy in Sub-Saharan Africa.

Authors:  Merrill Singer
Journal:  Infect Dis Poverty       Date:  2013-11-15       Impact factor: 4.520

5.  Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa.

Authors:  Didier K Ekouevi; Patrick A Coffie; Boris K Tchounga; Armel Poda; Antoine Jaquet; François Dabis; Serge P Eholie
Journal:  J Public Health Afr       Date:  2018-10-10

6.  Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.

Authors:  Edwige T Yelemkoure; Albert T Yonli; Hermann K Sombie; Issoufou Tao; Abdou Azaque Zouré; Abdoul Karim Ouattara; Abel P Sorgho; Arsène W Zongo; Moctar T A Zeba; Isabelle T Kiendrebeogo; Prosper Bado; Madeleine K Kabré; Théodora M Zohoncon; Florencia W Djigma; Dorcas Obiri-Yeboah; Jacques Simpore
Journal:  Intervirology       Date:  2021-09-28       Impact factor: 2.294

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.